vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement

Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026